Wardon Ojedapo, PA
Medical · Las Vegas, NVNPI 1164001392
Payments from drug & device makers
Across 489 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Amgen$1K
- Biohaven Pharmaceuticals, Inc.$987
- Corcept Therapeutics$737
- Dexcom, Inc.$660
- plus $5K from 32 others
What the payments were for
- Consulting fees$8007%
- Food & beverage$10,30586%
- Education$8527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 62 | $1,442 |
| Novo Nordisk | 59 | $1,409 |
| Amgen(2 entities) | 29 | $1,374 |
| Biohaven Pharmaceuticals, Inc. | 9 | $987 |
| Corcept Therapeutics | 16 | $737 |
| Dexcom, Inc. | 31 | $660 |
| Mannkind Corporation | 25 | $619 |
| Lilly USA, LLC | 34 | $572 |
| AbbVie | 41 | $533 |
| Antares Pharma, Inc. | 34 | $508 |
| Radius Health, Inc. | 15 | $298 |
| Sanofi-aventis U.S. LLC | 12 | $280 |
| Bayer | 11 | $275 |
| Boehringer Ingelheim | 18 | $275 |
| Xeris Pharmaceuticals, Inc. | 16 | $264 |
| Ultragenyx Pharmaceutical Inc. | 8 | $243 |
| Recordati_rare_diseases_inc. | 6 | $204 |
| IBSA Pharma Inc. | 9 | $167 |
| EUSA Pharma (US) LLC | 5 | $135 |
| Lifescan, Inc. | 5 | $119 |
| Chiasma, Inc. | 1 | $117 |
| Esperion Therapeutics, Inc. | 6 | $96 |
| Novartis | 6 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $83 |
| Medtronic | 4 | $82 |
| Alfasigma USA, Inc. | 3 | $60 |
| Tandem Diabetes Care, Inc. | 3 | $54 |
| Amneal Pharmaceuticals LLC | 3 | $47 |
| Amryt Pharma Holdings Ltd | 2 | $45 |
| Insulet Corporation | 2 | $33 |
| Acerus Pharmaceuticals Corporation | 1 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Bigfoot Biomedical Inc | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Nevro Corp. | 1 | $19 |
| Pfizer | 1 | $14 |
| GRT US Holding, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,957 in reported general payments places this provider in the 95th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 247 | $450,493 |
| MounjaroTirzepatide | 216 | $311,079 |
| JardianceEmpagliflozin | 159 | $238,844 |
| ProliaDenosumab | 132 | $231,828 |
| TrulicityDulaglutide | 104 | $164,128 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 67 | $106,089 |
| RybelsusSemaglutide | 33 | $65,114 |
| FarxigaDapagliflozin Propanediol | 35 | $49,994 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $48,932 |
| TradjentaLinagliptin | 39 | $44,824 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $39,956 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $34,953 |
| Novolog FlexpenInsulin Aspart | 78 | $33,647 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 136 | $30,918 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $27,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,409 | $523,346302 claims |
| Lilly USA, LLCMounjaro, Trulicity | $572 | $475,207320 claims |
| Boehringer IngelheimJardiance, Tradjenta | $275 | $283,668198 claims |
| AmgenProlia | $1,374 | $231,828132 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $280 | $112,725111 claims |
| AstraZenecaFarxiga | $1,442 | $49,99435 claims |
| AbbVieSynthroid | $533 | $3,34129 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $47 | $3,233345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
- Isaac TunnellLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.